ZCM
VYGR icon

Zebra Capital Management’s Voyager Therapeutics VYGR Stock Holding History

Zebra Capital Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-53,360
Closed -$220K – 218
2021
Q2 		$220K Sell
53,360
-5,764
-10% -$26.1K 0.26% 133
2021
Q1 		$278K Buy
+59,124
New +$403K 0.31% 116

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Zebra Capital Management's VYGR Position: Q3 2021 in Review

Zebra Capital Management sold out of Voyager Therapeutics (VYGR) in Q3 2021, closing a stake of 53,360 shares — an estimated $220K sold.

Zebra Capital Management first reported a position in VYGR in Q1 2021 and held it in 2 quarters. The position peaked at $278K in Q1 2021. 69 funds tracked by Wall St. Rank hold VYGR as of Q3 2021.

  • Zebra Capital Management reported no remaining Voyager Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Zebra Capital Management sold 53,360 Voyager Therapeutics shares in Q3 2021, an estimated $220K.
  • Zebra Capital Management first reported a position in Voyager Therapeutics in Q1 2021 and held it in 2 quarters.
  • Zebra Capital Management's Voyager Therapeutics position peaked at $278K in Q1 2021.
  • 69 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2021.

Based on Zebra Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.